Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
Chunlong Ma, Zilei Xia, M. Sacco, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 49, pp. 20697-20709
Open Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
Haozhou Tan, Yanmei Hu, Prakash D. Jadhav, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7561-7580
Open Access | Times Cited: 115
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 99
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Kai S. Yang, Sunshine Z. Leeuwon, Shiqing Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8686-8698
Open Access | Times Cited: 93
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Baoxue Quan, Huiping Shuai, Anjie Xia, et al.
Nature Microbiology (2022) Vol. 7, Iss. 5, pp. 716-725
Open Access | Times Cited: 80
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
Xiaojing Pang, Wei Xu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115491-115491
Open Access | Times Cited: 57
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 46
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo Augusto Massarico Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 41
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 40
Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, et al.
Nature Microbiology (2024) Vol. 9, Iss. 4, pp. 1075-1088
Open Access | Times Cited: 28
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity
Shenghua Gao, Katharina Sylvester, Letian Song, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13343-13364
Closed Access | Times Cited: 63
SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies
Bin Tan, Ryan Joyce, Haozhou Tan, et al.
Accounts of Chemical Research (2022) Vol. 56, Iss. 2, pp. 157-168
Open Access | Times Cited: 61
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, et al.
ChemMedChem (2022) Vol. 17, Iss. 22
Open Access | Times Cited: 44
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 24
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 22
Sulfamate Acetamides as Self-Immolative Electrophiles for Covalent Ligand-Directed Release Chemistry
Rambabu Reddi, Adi Rogel, Ronen Gabizon, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 6, pp. 3346-3360
Open Access | Times Cited: 21
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
Yugendar R. Alugubelli, Zhi Geng, Kai S. Yang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114596-114596
Open Access | Times Cited: 36
Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2
Santanu Mondal, Yongzhi Chen, G.J. Lockbaum, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 46, pp. 21035-21045
Open Access | Times Cited: 35
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals
Yuying Ma, Kai S. Yang, Zhi Geng, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114570-114570
Open Access | Times Cited: 32
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
Tika R. Malla, Lennart Brewitz, Dorian-Gabriel Muntean, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7682-7696
Open Access | Times Cited: 31
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease
Yuya Hirose, Naoya Shindo, Makiko Mori, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13852-13865
Closed Access | Times Cited: 31
A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid
Joseph R. A. Kincaid, Juan C. Caravez, Karthik S. Iyer, et al.
Communications Chemistry (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 31
The expanding repertoire of covalent warheads for drug discovery
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top